Compare Live Nation Entertainment, Inc. (LYV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Viatris Inc — how do they compare? Live Nation Entertainment, Inc. trades at $184.11 (market cap $42.71B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.3× Viatris Inc's market cap, and Viatris Inc pays a 2.95% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | VTRS | |
|---|---|---|
Market Cap | $42.71B | $18.69B |
Sector | Industrials | Health |
52-Week High | $186.59 | $17.86 |
52-Week Low | $125.61 | $9.49 |
Enterprise Value | $44.92B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYV trades at $184.64, up 2.2% on the day, with a bullish technical signal from moving averages and strong analyst support (86.96% buy ratings). The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by record concert demand. However, valuation metrics like a P/E of 117.49 and negative ROE of -116.65% highlight significant premium pricing and profitability challenges.
Outlook remains positive due to robust live event demand and raised full-year expectations, but risks include high debt, legal uncertainties, and margin pressure. The consensus price target of $209.54 suggests ~13.5% upside, though investors should weigh growth potential against elevated valuation and operational risks.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
